Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk
Nature Genetics2010Vol. 42(6), pp. 492–494
Citations Over TimeTop 1% of 2010 papers
Amy L. Sherborne, Fay J. Hosking, Rashmi B. Prasad, Rajiv Kumar, Rolf Koehler, Jayaram Vijayakrishnan, Elli Papaemmanuil, Claus R. Bartram, Martin Stanulla, Martin Schrappe, Andreas Gast, Sara E. Dobbins, Yussanne Ma, Eamonn Sheridan, Malcolm Taylor, Sally E. Kinsey, T. Lightfoot, Eve Roman, Julie Irving, James M. Allan, Anthony V. Moorman, Christine J. Harrison, Ian Tomlinson, Sue Richards, Martin Zimmermann, Csaba Szalai, Ágnes F. Semsei, Dániel J. Erdélyi, Maja Krajinović, Daniel Sinnett, Jasmine Healy, Anna González‐Neira, Norihiko Kawamata, Seishi Ogawa, H. Phillip Koeffler, Kari Hemminki, Mel Greaves, Richard S. Houlston
Related Papers
- → P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas(2023)48 cited
- → CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma(2023)9 cited
- → FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma(2023)5 cited
- → Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma(2006)10 cited
- → F.3 Comprehensive multiplatform analysis of CDKN2A alterations in meningiomas(2023)